Genprex (GNPX) 8-K Summary (Nov 4, 2025)
Genprex announced a significant Intellectual Property (IP) development regarding its lead candidate:
- The European Patent Office has communicated its intent to grant a patent for Reqorsa® Gene Therapy when used in combination with PD-1 antibodies for cancer treatment.
- This reinforces existing IP protection across multiple major jurisdictions (US, Japan, China, etc.).
- Reqorsa is primarily developed for lung cancer, leveraging synergy with existing immunotherapies.
Investor Note: The filing contains standard forward-looking s
...